Anal cancer and rectal cancer are not the same disease. Despite developing just inches apart in the body, they originate from different types of cells, have different primary causes, and are treated in fundamentally different ways. The confusion is understandable because the anal canal and rectum are connected, and symptoms can overlap. But medically, these are distinct cancers with their own staging, treatment plans, and outlooks.
Where Each Cancer Starts
The rectum is the final straight portion of the large intestine, sitting just above the pelvic floor. The anal canal begins where the rectum passes through the pelvic floor muscles and ends at the anal opening. The boundary between them is marked by a structure called the dentate line, a ring of tissue that represents a real dividing line in the body’s development: everything above it formed from one type of embryonic tissue, and everything below from another.
This developmental difference is the root of why these two cancers behave so differently. The rectum and upper anal canal are lined with a single layer of column-shaped cells (the same type found throughout the intestines). The lower anal canal is lined with flat, layered cells called squamous cells, more like skin. When cancer develops, the type of cell it grows from shapes nearly everything about the disease.
Different Cell Types, Different Diseases
The most common type of anal cancer is squamous cell carcinoma, which arises from those flat, skin-like cells lining the lower anal canal. Rectal cancer, by contrast, is almost always adenocarcinoma, a cancer that grows from the glandular cells lining the inside of the intestine. This distinction matters enormously because squamous cell cancers and adenocarcinomas respond to different treatments, spread through different pathways, and carry different prognoses.
Even the way these cancers spread through the body differs. Rectal cancers tend to drain into lymph nodes deep in the pelvis and along the major blood vessels of the abdomen. Anal cancers below the dentate line typically spread first to the inguinal lymph nodes in the groin, which are closer to the surface and easier to detect on physical exam.
What Causes Each Cancer
The primary driver of anal cancer is the human papillomavirus (HPV), particularly types 16 and 18. About 91% of anal cancers are thought to be caused by HPV, according to the CDC. This makes anal cancer fundamentally a virus-driven disease and, importantly, one that can be prevented through HPV vaccination. Other risk factors include a weakened immune system (from HIV or immunosuppressive medications) and a history of multiple sexual partners.
Rectal cancer has a very different risk profile. Its major drivers include age, family history, inherited genetic conditions like Lynch syndrome, a diet high in processed meat and low in fiber, obesity, smoking, and heavy alcohol use. HPV plays little to no role in typical rectal adenocarcinoma. While both cancers share some general risk factors like smoking, the core biology pushing each one is distinct.
How Symptoms Compare
Both cancers can cause rectal bleeding, which is one reason people confuse them. But the pattern of other symptoms tends to differ. Anal cancer often causes pain or pressure in the anal area, itching around the anus, a lump or mass near the anal opening, and changes in bowel habits. Some people notice discharge from the anus.
Rectal cancer is more likely to cause changes in stool shape (narrower than usual), a persistent feeling that the bowel hasn’t fully emptied, and unexplained weight loss. Bleeding from rectal cancer often shows up as dark or maroon-colored blood mixed into the stool, while anal cancer bleeding may appear brighter red and on the surface. Neither set of symptoms is perfectly reliable for self-diagnosis, since hemorrhoids and other benign conditions can mimic both.
Screening and Detection
The screening approaches for these cancers are completely different. Rectal cancer is caught through standard colorectal cancer screening: colonoscopy, stool-based tests, or flexible sigmoidoscopy. These are recommended for average-risk adults starting at age 45.
Anal cancer screening is newer and more targeted. It often starts with an anal Pap test, similar to a cervical Pap smear. A swab collects cells from the anal canal, and a pathologist examines them under a microscope for precancerous changes. This can be combined with HPV testing to check for high-risk viral strains. If either test comes back abnormal, the next step is high-resolution anoscopy, a close-up examination of the anal canal with a magnifying scope, during which biopsies can be taken. Home-based self-swab kits are also being developed to make anal cancer screening more accessible, particularly for high-risk groups like people living with HIV.
Treatment Is Fundamentally Different
This is where the distinction between these two cancers matters most for patients. Anal squamous cell carcinoma responds well to a combination of radiation therapy and chemotherapy given together, often called chemoradiation. For most people with anal cancer, this is the primary treatment, and surgery is reserved for cases where chemoradiation doesn’t fully eliminate the tumor. The goal is to cure the cancer while preserving the sphincter muscles and normal bowel function.
Rectal cancer treatment typically centers on surgery to remove the tumor and surrounding tissue. Because rectal tumors have a higher chance of recurring after surgery, many patients receive chemotherapy or radiation (or both) before the operation to shrink the tumor and reduce that risk. Some early-stage rectal cancers can be removed with minimally invasive techniques, but more advanced cases may require removal of part of the rectum, sometimes with a temporary or permanent ostomy bag.
The difference in treatment approach comes directly from the cell type. Squamous cells are inherently more sensitive to radiation than the glandular cells that form adenocarcinomas, which is why radiation works so well as a frontline therapy for anal cancer but plays more of a supporting role in rectal cancer.
Survival Rates and Outlook
When anal cancer is caught while still localized (confined to the anal canal), the five-year relative survival rate is 85%. If it has spread to nearby lymph nodes (regional stage), that drops to about 70%. These numbers reflect the fact that anal cancer generally responds well to chemoradiation, even at more advanced stages.
Rectal cancer survival varies widely by stage as well. Localized rectal cancer has a five-year survival rate in a similar range, but outcomes diverge more sharply at advanced stages. Both cancers benefit enormously from early detection, which is why understanding that these are two separate diseases, with different screening methods and risk factors, can make a real difference.
Why the Distinction Matters for You
If you or someone you know has been told they have cancer in this part of the body, knowing whether it’s anal or rectal cancer affects every decision going forward: what specialist you see, what treatment you receive, and what prevention looks like for family members. A colorectal surgeon handles rectal cancer. Anal cancer may be managed by a radiation oncologist working alongside a medical oncologist, with surgery as a backup rather than a first option.
For prevention, the paths are equally different. Reducing rectal cancer risk means colonoscopy screening, a healthy diet, maintaining a normal weight, and limiting alcohol. Reducing anal cancer risk starts with HPV vaccination, ideally before age 26, though it’s now approved for adults up to 45 in certain situations. For people at higher risk of anal cancer, regular anal Pap tests can catch precancerous changes early, much the way cervical screening has dramatically reduced cervical cancer rates over the past several decades.